RESEARCH ARTICLE

Open Access



Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review

Chaogang Yang¹⁺, Kun Zou²⁺, Liang Zheng¹ and Bin Xiong^{1*}

Abstract

Background: Circulating tumor cells (CTCs) have been accepted as a prognostic marker in patients with metastatic colorectal cancer (mCRC, UICC stage IV). However, the prognostic value of CTCs in patients with non-metastatic colorectal cancer (non-mCRC, UICC stage I-III) still remains in dispute. A meta-analysis was performed to investigate the prognostic significance of CTCs detected by the RT-PCR method in patients diagnosed with non-mCRC patients.

Methods: A comprehensive literature search for relevant articles was performed in the EmBase, PubMed, Ovid, Web of Science, Cochrane library and Google Scholar databases. The studies were selected according to predetermined inclusion/exclusion criteria. Using the random-effects model of Stata software, version12.0 (2011) (Stata Corp, College Station, TX, USA), to conduct the meta-analysis, and the hazard ratio (HR), risk ratio (RR) and their 95% confidence intervals (95% Cls) were regarded as the effect measures. Subgroup analyses and meta-regression were also conducted to clarify the heterogeneity.

Results: Twelve eligible studies, containing 2363 patients with non-mCRC, were suitable for final analyses. The results showed that the overall survival (OS) (HR = 3.07, 95% CI: [2.05–4.624], P < 0.001; $I^2 = 55.7\%$, P = 0.008) and disease-free survival (DFS) (HR = 2.58, 95% CI: [2.00–3.32], P < 0.001; $I^2 = 34.0\%$, P = 0.085) were poorer in patients with CTC-positive, regardless of the sampling time, adjuvant therapy and TNM stage. CTC-positive was also significantly associated with regional lymph nodes (RLNs) metastasis (RR = 1.62, 95% CI: [1.17–2.23], P = 0.003; $I^2 = 74.6\%$, P < 0.001), depth of infiltration (RR = 1.41, 95% CI: [1.03–1.92], P = 0.03; $I^2 = 38.3\%$, P = 0.136), vascular invasion (RR = 1.66, 95% CI: [1.17–2.36], P = 0.004; $I^2 = 46.0\%$, P = 0.135), tumor grade (RR = 1.19, 95% CI: [1.02–1.40], P = 0.029; $I^2 = 0\%$, P = 0.821) and tumor-node-metastasis (TNM) stage(I, II versus III) (RR = 0.76, 95% CI 0.71–0.81, P < 0.001; $I^2 = 0\%$, P = 0.30; $I^2 = 0\%$, P = 0.30; $I^2 = 0\%$, P = 0.528). (Continued on next page)

* Correspondence: binxiong1961@whu.edu.cn

¹Department of Gastrointestinal Surgery & Department of Gastric and Colorectal Surgical Oncology, Zhongnan Hospital of Wuhan University; Hubei Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study Center, No.169 Donghu Road, Wuchang District, Wuhan 430071, China Full list of author information is available at the end of the article



© The Author(s). 2017 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

[†]Equal contributors

(Continued from previous page)

Conclusions: Detection of CTCs by RT-PCR method has prognostic value for non-mCRC patients, and CTC-positive was associated with poor prognosis and poor clinicopathological prognostic factors. However, the prognostic value of CTCs supports the use of CTCs as an indicator of metastatic disease prior to the current classification of mCRC meaning it is detectable by CT/MRI.

Keywords: Circulating tumor cells, Non-metastatic colorectal cancer, RT-PCR, Prognosis, Meta-analysis

Background

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the fourth leading cause of cancerrelated death [1]. In China, CRC is ranked fourth in morbidity and mortality among the gastrointestinal cancers [2]. Due to the difficulties of early diagnosis, a large proportion of patients with CRC are undiagnosed until an advanced stage. Due to the continuous improvement of the treatment methods, decreasing CRC mortality rates have been observed in a large number of countries worldwide [3], especially for the patients with nonmetastatic colorectal cancer (non-mCRC, UICC I-III). Unfortunately, the 5-year overall survival (OS) of nonmCRC patients is still low and approximately 25-50% of patients with stage II-III CRC will experience recurrence or distant metastasis after comprehensive treatment [4], which is the main reason for studying the prognosis in those patients. The mechanisms of recurrence and metastasis of CRC are very complicated and remains unclear. Recurrence and metastasis may involve series of cell biological behaviors, including circulating tumor cells (CTCs), which have been gradually recognized to play an important role in the process of distant metastasis, according to the "seed and soil theory" [5].

CTCs, which were defined as the "break away" cancer cells in the peripheral blood (PB) of cancer patients, were firstly proposed by Ashworth in1869 [6] and further demonstrated by Engell in 1955 [7]. These cells, which shed intermittently from the solid tumors, circulate in the bloodstream, and arrive at different positions, are the main cause of distant metastases [8]. However, the lower concentration of PB in the solid tumors, which are confined to local growth [9, 10], makes it difficult to detect in early CRC. During the past few decades, with a variety of highly sensitive and specific diagnostic approaches including reverse transcriptase-polymerase chain reaction (RT-PCR), immunocytochemistry, flow cytometry, and the CellSearch system, the efficiency of detecting CTCs is increasing gradually. Encouraging results from numerous studies have demonstrated that the presence of CTCs was significantly associated with poor prognosis of CRC patients. However, most large-scale data were collected from patients with mCRC [11, 12], there were only limited data on the significance of CTC in patients with non-mCRC. In those studies, the

diagnostic method used to detect CTCs was predominantly the CellSearch system [13-15], which is the first and only method approved by the US Food and Drug Administration (FDA) for evaluating the prognosis of CRC patients [16]. However, while there are advantages of high specificity and reproducibility for CTC detection, as a semi-automated system, CellSearch has the disadvantages of moderate sensitivity and subjective verification. Compared to CellSearch, RT-PCR has higher sensitivity and is more objective for detection of CTCs [17, 18]. Therefore, it has also been widely used for the detection of CTCs for non-mCRC patients, and the clinical utility has been demonstrated in several studies. Shimada et al. reported that CTCs detection with the RT-PCR method was correlated with tumor metastasis and prognosis [19]. However, Kust et al. showed that CTCs detected with RT-PCR had unfavorable prognostic significance for non-mCRC patients [20]. Therefore, the prognostic role of CTC detection with RT-PCR in non-mCRC is still controversial.

We performed a pooled analysis of published studies to quantitatively and comprehensively summarize the prognostic relevance of CTCs detected by RT-PCR in patients with non-mCRC.

Methods

Search strategy

A literature search for relevant studies was performed systematically from the EmBase, PubMed, Ovid, Web of Science, Cochrane library and Google Scholar database with key words "colorectal cancer", "circulating tumor cells" or "CTCs" and "polymerase chain reaction or PCR" by two researchers (CG Yang and K Zou) independently (up to July, 2016). No time restriction was imposed. In order to prevent missing relevant studies, "related articles" function of PubMed and Google Scholar were used to identify other potentially relevant publications.

Inclusion and exclusion criteria

The inclusion criteria for our meta-analysis were: (1) investigated the clinicopathological or prognostic significance of CTC detection in non-mCRC patients; (2) used any form of RT-PCR for detecting CTCs; (3) hazard ratio (HR) or a risk ratio(RR) with a 95% confidence

interval (95% CI) of OS or/and disease-free survival (DFS) reported in the study or had sufficient data to calculate; (4) collected the samples from PB. Exclusion criteria were: (1) studies including mCRC patients; (2) the number of patients was less than 20. (3) exclusion of letters, reviews, and articles published with non-English language. (4) the study was redundant, based on the same database or patient population as an included study. To avoid the inclusion of redundant studies, all the included studies were checked carefully, including their authors, organizations, accrual period, and population of patients.

Data extraction and quality assessment

Two reviewers (CG Yang and K Zou) evaluated the quality of the included studies and extracted data independently. The following information was collected: first author, year of publication, country, characteristics of the study population (number, sex and age), TNM stage (UICC), detection markers, adjuvant therapy, sampling time (pre/intra/post-operation), rate of CTC positivity rate, follow-up period, the HR and their associated standard errors on prognostic outcomes (OS or/and DFS). If the HRs and its 95% CI were not directly provided in the original articles, we used the method designed by Jayne F. Tierney [21] to calculate them from the available data. In addition, when HRs were presented by both univariate and multivariate analyses, the latter ones were preferable because multivariate analyses also considered possible confounding of exposure effects [22]. The quality assessment was based on the Newcastle-Ottawa Scale (NOS) criteria, which is recommended by the Cochrane Library for the cohort study, score 5-9 is considered as high quality and 1-4 is low quality [23]. The results of quality assessment and data extraction were confirmed by two reviewers. Any disagreements about data extraction and quality assessment were resolved by comprehensive discussion and were checked by the third investigator.

Statistical analysis

Statistical analyses were implemented with Stata software, version 12.0 (2011) (Stata Corp, College Station, TX, USA). The RR and HR were regarded as effect measures for summarizing the clinicopathological and prognostic significance of CTCs detected by RT-PCR in non-mCRC. By convention, a HR >1 indicates a poorer prognosis in the CTC-positive group in contrast with negative group and a RR >1 implies CTC-positive be associated with a parameter. All statistical values were reported with 95% confidence intervals (95% CIs) and *P* value < 0.05 was considered statistically significant. To retain maximum information, we added additional information into included study from

original authors or excluded studies if the included and excluded studies were based on the same patients' population and some information of interest was reported in the excluded studies but not in the included studies. All relevant studies were included in the overall analysis. Subgroup analyses were performed based on the sampling time (pre/intra/post-OP), TNM stage (II/III), adjuvant therapy (without/ post-OP chemotherapy) and detection markers (single/multiple). All data analyses used a random effects model, because it provided more conservative estimates and more tailored to multicenter studies in which heterogeneity was usually present [24]. The Cochrane's Q statistic and I^2 statistic were applied to evaluate the heterogeneity among studies. P value < 0.01 for the Q statistic and/or $I^2 > 50\%$ were considered significant heterogeneity [25]. The I² value indicated the degree of heterogeneity. Potential heterogeneity between-study was illustrated by forest plots. If necessary, meta-regression was performed to explore the potential source of heterogeneity. Lastly, we evaluated potential publication bias by a funnel plot, which was further validated by the Egger [26] and Begg's test [27].

Results

Baseline characteristics of the eligible studies

Initially, 206 relevant studies were identified in the systematic literature search process. By checking the titles and abstracts, 164 studies were excluded and 42 potential studies were retrieved. An additional 30 studies were then excluded after they were fully reviewed because they lacked sufficient data (2 studies), were redundant (2 studies), or included stage IV patients (26 studies). Finally, 12 studies were yielded as meeting our inclusion criteria and were eligible for our meta-analysis (Fig. 1).

Twelve eligible studies, including 23 sets of data, contained 2363 patients with non-mCRC [19, 20, 28–37]. The studies were conducted in seven countries (Australia, China, Croatia, Germany, Japan, Spain and the UK) and were published between 2002 and 2016. All studies detected tumor cells from PB with the molecular detection method (PCR, RT-PCR, or RT followed by quantitative PCR). Table 1 summarizes the main baseline characteristics and study design variables. The quality of the eligible cohort studies was assessed with NOS and is summarized in Table 2.

Effects of CTCs on OS and DFS for non-mCRC patients

Data on OS were available in 13 sets of data included in eight studies [19, 20, 28–30, 33, 35, 36]. The pooled analysis showed CTC-positive was significantly associated with a poor OS (HR = 3.07, 95% CI: [2.05–4.624], P < 0.001), with significant between-study heterogeneity (I² = 55.7%, P = 0.008; Fig. 2a) in non-mCRC patients.



Seventeen sets of data included in all enrolled studies contained the data on DFS [19, 20, 28–37]; the pooled analysis indicated CTC-positive was also associated with a significantly decreased DFS (HR = 2.58, 95% CI: [2.00–3.32], P < 0.001) with no between-study heterogeneity (I² = 34.0%, P = 0.085; Fig.

2b). To further investigate the effect of CTCs detection on the prognosis of non-mCRC patients under different conditions, subgroup analyses were performed based on different sampling time (pre-OP and intra/post-OP), TNM stage (II/III) and adjuvant therapy status (without/post-OP chemotherapy). The results demonstrated CTC-positive was significantly associated with poor OS (HR = 3.65, 95% CI: [2.49-5.36], P < 0.001; HR = 2.44, 95% CI: [1.19–4.99], P =0.015; Fig. 3a) and DFS (HR = 3.08, 95% CI: [2.21-4.31], *P* < 0.001; HR = 2.23, 95% CI: [1.50–3.29], *P* < 0.001; Fig. 3b) in non-mCRC patients, regardless of pre-OP or intra/post-OP sample collection. Furthermore, due to the limited number of studies on about neoadjuvant radiotherapy or/and chemotherapy and post-OP adjuvant radiotherapy in the included studies, we conducted a subgroup analysis to evaluate to prognostic value of CTCs in patients who did and did not receive post-operative chemotherapy. The results showed no difference between these two groups (OS, HR = 2.96, 95% CI: [1.96–4.47], P < 0.001; HR = 3.59, 95% CI: [2.26–5.71], P = 0.015; Fig. 3c. DFS, HR = 2.83, 95% CI: [1.92–4.19], P < 0.001; HR = 3.19, 95% CI: [2.26–4.50], P < 0.001; Fig. 3d). For TNM stage, subgroup analyses were only performed to explore the prognostic value of CTCs for stage II and III CRC patients; the results demonstrated that CTC-positive was significantly associated with poor OS (HR = 3.72, 95% CI: [2.36–5.85], P < 0.001; HR = 2.94, 95% CI: [2.09–4.14], P < 0.001; Fig. 3e) and DFS (HR = 2.77, 95% CI: [1.90–4.02], P < 0.001; HR = 3.00, 95% CI: [2.19–4.11], P < 0.001; Fig. 3f) for both stage II and III CRC patients.

Association between CTCs and clinicopathological parameters

Seven studies [19, 28, 29, 31, 35-37] including eight sets of data were evaluated to determine the relationship between CTC-positive and regional lymph nodes metastasis. The results showed regional lymph nodes metastasis was associated with CTC-positive (RR = 1.62, 95% CI: [1.17-2.23], P = 0.003) with significant betweenstudy heterogeneity ($I^2 = 74.6\%$, *P*<0.001; Fig. 4a). The depth of tumor infiltration was associated with CTC-positive (RR = 1.41, 95% CI: [1.03–1.92], *P* = 0.03; I² = 38.3%, *P* = 0.136; Fig. 4b). Studies assessed by pooled analysis showed significant association between CTC-positive and vascular invasion (RR = 1.66, 95% CI: [1.17-2.36], P = 0.004; $I^2 = 46.0\%$, P = 0.135; Fig. 4c). Eight sets of data from seven studies [19, 28, 29, 31, 35-37] demonstrated that tumor grade was associated with CTC-positive (RR = 1.19, 95% CI: [1.02-1.40], P = 0.029; $I^2 = 0\%$, P = 0.821; Fig. 4d). Eight studies [19, 20, 28, 29, 31, 35-37] reported the relationship between CTC-positive and TNM stage (I, II versus III). As shown in Fig. 3e, CTC-positive in stage III is greater than in stage I and II (RR = 0.76, 95% CI: [0.71–0.81], P < 0.001; $I^2 = 0\%$, P = 0.717; Fig. 4e). Furthermore, the pooled analysis found no significant relationship between CTC-positive and tumor size (RR = 1.08, 95% CI: [0.94–1.24], P = 0.30; $I^2 = 0\%$, P =0.528; Fig. 4f).

Exploring the sources of heterogeneity

To examine the intra-study inconsistencies on OS, we stratified the eligible studies according to variables as shown in Table 3. The pooled analyses results showed the heterogeneity did not drop to an insignificant level, regardless of the variables. Therefore, meta-regression was further implied to explore the source of heterogeneity on OS. As shown in Table 4, for the studies on OS, only positive rate of CTC detection was significantly correlated with intra-study variability (P = 0.021), and it explained 93.8% of the between-study variance in the multivariate analysis.

Table 1 Baseline chat	racteristics c	of the included studies										
Article	Country	Number (M/F) ^a	Age Mean ± SD ^b / Median (range) (y ^c)	TS ^d	Markers	Adjuvant therapy	ST ^e	Rate (+) ^f	OM ^g	HR ^h estimate	CS	MA
Kust 2016 [33]	Croatia	82(49/33)	Mean:66 ± 9.6	Ē	CK20	Post-OP ^k CT ^I for III and part of II	Pre-OP	22 (26.83%)	OS ^m DFS ⁿ	Data extrapolated	Yes	No
Liu 2013 [28]	China	92(60/32)	Mean:66 ± 9.6	=	CK20	I	Pre-OP	31 (25%)	OS DFS	Reported in text	Yes	Yes
Liu 2013 (1) [28]	China	41(NR)	NR ^o	=	CK20	Without	I	NR	OS DFS	Reported in text	Yes	Yes
Liu 2013 (2) [28]	China	51(NR)	NR	=	CK20	Post-OP CT	I	NR	OS DFS	Reported in text	Yes	Yes
Yokobori (1) 2013 [29]	Japan	Training: 151(86/65)	Mean:66.76 ± 11.02	=	PLS3	Without	Pre-OP	33 (21.85%)	OS DFS	Reported in text	Yes	Yes
Yokobori (2) 2013 [29]	Japan	Training: 131(75/56)	Mean:66.76 ± 11.02	≡	PLS3	Post-OP CT	Pre-OP	38 (29%)	OS DFS	Reported in text	Yes	Yes
Yokobori (3) 2013 [29]	Japan	Validation: 158(96/62)	Mean:67.51 ± 11.08	=	PLS3	Without	Pre-OP	35 (22.15%)	OS DFS	Reported in text	Yes	Yes
Yokobori (4) 2013 [29]	Japan	Validation: 103(63/40)	Mean:67.51 ± 11.08	≡	PLS3	Post-OP CT	Pre-OP	30 (29.12%)	OS DFS	Reported in text	Yes	Yes
Shimada (1) 2012 [19]	Japan	111(60/51)	Median:68(27–82)	=	CEA, CK19, CK20, CD133	Without	Post-OP	63 (56.76%)	OS DFS	Reported in text	Yes	Yes
Shimada (2) 2012 [19]	Japan	86(47/39)	Median:68(27–82)	≡	CEA, CK19, CK20, CD133	Post-OP CT	Post-OP	61 (70.93%)	OS DFS	Reported in text	Yes	Yes
linuma (1) 2011 [30]	Japan	Training: 420(224/196)	Mean:66.0 ± 12.4	=	CEA, CK19, CK20, CD133	I	Post-OP	106 (25.24%)	OS DFS	Reported in text	Yes	Yes
linuma (1–1) 2011 [30]	Japan	Training: 176(NR)	NR	=	CEA, CK19, CK20, CD133	Without	I	NR	OS DFS	Reported in text	Yes	Yes
linuma (1–2) 2011 [30]	Japan	Training:150(NR)	NR	=	CEA, CK19, CK20, CD133	Post-OP CT	I	NR	OS DFS	Reported in text	Yes	Yes
linuma (2) 2011 [30]	Japan	Validation: 315(175/140)	Mean:66.0 ± 12.4	=	CEA, CK19, CK20, CD133	I	Post-OP	75 (23.81%)	OS DFS	Reported in text	Yes	Yes
linuma (2–1) 2011 [30]	Japan	Validation: 143(NR)	NR	=	CEA, CK19, CK20, CD133	Without	I	NR	OS DFS	Reported in text	Yes	Yes
linuma (2–2) 2011 [30]	Japan	Validation: 97(NR)	NR	=	CEA, CK19, CK20, CD133	Post-OP CT	I	NR	OS DFS	Reported in text	Yes	Yes
Uen 2008 [31]	China	438(234/204)	NR	≡ -	CK19, CK20, CEA, hTERT	Post-OP CT for III and part of II	Post-OP (1 W ^p)	137 (31.27%)	DFS	Reported in text	Yes	Yes
Barreto 2007 [32]	Ъ	113(NR)	Mean:67	≡ ±	CEA, CK20	Post-OP CT for III and part of II	Post-OP (24 h ^q)	34 (30.09%)	DFS	Reported in text	Yes	Yes

Table 1 Baseline cha	rracteristics c	of the included studies (Cor	ntinued)									
Article	Country	Number (M/F) ^a	Age Mean ± SD ^b / Median (range) (y ^c)	TS ^d	Markers	Adjuvant therapy	ST ^e	Rate (+) ^f	OM ^g	HR ^h estimate	CS	MA ^j
Koch 2006 [33]	Germany	90(59/31)	Mean:66.1	=	CK20	Post-OP CT for rectal cancer	Post-OP	28 (31.1%)	os DFS	Reported in text	Yes	^o N
Lloyd 2006 [34]	Australia	125 (74/51)	Median:74 (43–95)	<u> </u>	CK20, CEA, EphB4, LAMγ2, MAT	Without	Pre-OP	5 (4%)	DFS	Data extrapolated	Yes	No No
Sadahrio 2005 [35]	Japan	100(NR)	NR	Ē	CEA	NR	Intra-OP	39 (39%)	OS DFS	Data extrapolated	Yes	Yes
Bessa 2003 [36]	Spain	66 (23/43)	Median:73	≡ ⊥	CEA	Post-OP CT for III and part of II	Post-OP	36 (54.55%)	OS DFS	Reported in text	Yes	Yes
lto 2002 [37]	Japan	99(62/37)	NR	Ē	CEA	NR	Post-OP	26 (26.26%)	DFS	Data extrapolated	Yes	N
NOTE: ^a <i>M/F</i> Male/female, ^J MA Multivariance analys	^b <i>SD</i> Standard is, ^k <i>OP</i> Operati	deviation, ^c Y Year, ^d TS Tumor ion, ^I CT Chemotherapy, ^m OS Ov	stage (UICC), ^e <i>ST</i> Samplii verall survival, ⁿ DFS Disea	ng time, ase-free	, ^f <i>Rate</i> (+) Rate of survival, ^o NR Not	f CTCs-positive pa reported, ^p W We	tients, ^g OM (ek, ^q h hour	Jutcome mea	sured, ^h H	R Hazard ratio, ⁱ CS Cura	itive sur	gery,

F Ĵ Ŧ ~ 2 _____ . f +h, ÷

Table 2 The assessment of the risk of bias in each Cohort study using the Newcastle-Ottawa Scale

Study	Selectio	on (0–4)			Compara	bility (0–2)	Outcom	e (0-3)	Total	
	REC	SNEC	AE	DO	SC	AF	AO	FU	AFU	
Kust 2016 [20]	0	1	1	1	0	0	0	1	0	4
Liu 2013 [28]	0	1	1	1	0	0	1	1	0	5
Yokobori 2013 [29]	1	1	1	1	0	0	1	1	0	6
Shimada 2012 [19]	1	1	1	1	0	0	1	1	1	7
limuna 2011 [30]	0	1	1	1	0	0	1	1	0	5
Uen 2008 [31]	0	1	1	1	0	0	1	1	0	5
Barreto 2007 [32]	0	0	1	1	0	0	1	1	0	4
Koch 2006 [33]	0	1	1	1	0	0	1	0	0	4
Lloyd 2006 [34]	0	0	1	1	0	0	1	0	0	3
Sadahrio 2005 [35]	1	1	1	1	0	0	1	1	1	7
Bessa 2003 [36]	0	1	1	1	0	0	1	1	0	5
lto 2002 [37]	0	1	1	1	0	0	1	1	0	5

NOTE: REC representativeness of the exposed cohort, SNEC selection of the non-exposed cohort, AE ascertainment of exposure; DO: demonstration that outcome of interest was not present at start of study, SC study controls for age, sex, AF study controls for any additional factors (chemoradiotherapy, curative resection), AO assessment of outcome, FU follow-up long enough (36 M) for outcomes to occur, AFU adequacy of follow-up of cohorts (\geq 90%).Total: the points of each study

Publication bias

Potential publication bias was assessed by Begg's and Egger's tests. P < 0.05 indicated the existence of publication bias. There was no evidence of publication bias for the pooled analysis of OS ($P_{\text{Begg}} = 0.246$, $P_{\text{Egger}} = 0.964$) and DFS ($P_{\text{Begg}} = 0.434$, $P_{\text{Egger}} = 0.301$). The funnel plots of publication bias on OS and DFS are shown in Fig. 5a and b, respectively.

Discussion

Currently, the treatment strategies for non-mCRC include radical surgery as well as neoadjuvant and adjuvant radio-chemotherapy. In clinical practice, the oncologist selects the most appropriate regiment depending on the TNM stage, which is based on the

extent of tumor invasion (T), the presence of metastases or micro-metastases in regional lymph nodes (N) and distant metastases (M) [38]. The clinical TNM stage, which is based on the imaging examination, can help oncologists assess whether neoadjuvant radio-chemotherapy should be incorporated before surgery, whereas the pathological TNM stage, which is based on the histopathologic examination of post-operative samples, provides information on whether adjuvant radio-chemotherapy should be included after curative resection. Despite advances in therapeutic approaches, it is estimated that approximately 30% of patients will develop metastases and eventually succumb to their disease after comprehensive treatment [39]. In general, the prognosis outcome of non-mCRC patients is directed by the TNM-stage, which provides the



$\frac{1}{2013} \frac{1}{1000} \frac{1}{10000} \frac{1}{1000} \frac{1}{100$	tudy A		HR (95% CI)	% Weight	Study ID B	HR (95% CI)	% Weight
$\frac{1}{2013} = \frac{1}{2013} = 1$	re-op	1 :			Pre-OP		
$\frac{1}{2} \frac{1}{2} \frac{1}$	het 2016		2 84 /0 85 0 53)	6 57	Kust 2016	3.14 (0.94, 10.47) 3.61
$\frac{1}{2} \frac{1}{2} \frac{1}$	iu 2013	1.	2.04 (0.05, 9.55)	5.99	Liu 2013	2.68 (1.17, 6.12)	6.28
$\frac{1}{22} \frac{1}{22} \frac{1}{2} \frac$	lu 2013		5.50 (1.40, 20.75)	3.00	Yokobori (2) 2013	2.73 (1.18, 6.33)	7 90
$\frac{1}{10} \frac{1}{10} \frac$	okobon (1) 2013		4.07 (1.47, 11.30)	7.89	Yokobori (3) 2013	4 46 (1 72 11 56) 5 16
$\frac{1}{122} 2011 + 221 + 122 +$	okobori (2) 2013		2.57 (1.42, 4.64)	11.77	Yokobori (4) 2013	4.37 (2.14, 8.91)	7.57
$\frac{1}{12} \frac{1}{12} \frac$	okobori (3) 2013		4.60 (1.32, 16.07)	6.32	Lloyd 2006	· 3.03 (0.23, 40.12) 0.92
$\frac{1}{12} \frac{1}{12} \frac$	okobori (4) 2013		7.01 (2.66, 18.46)	8.31	Subtotal (I-squared = 0.0%, p = 0.852)	3.08 (2.21, 4.31)	37.58
$\frac{1}{1000} = \frac{1}{1000} = \frac{1}{10000} = \frac{1}{10000} = \frac{1}{100000} = \frac{1}{10000000000000000000000000000000000$	ubtotal (I-squared = 0.0%, p = 0.578)	0	3.65 (2.49, 5.36)	46.74	Intra/post-OP		
$\frac{1}{10^{2}} \frac{1}{20^{2}} 1$	tra/post-op				Shimada (1) 2012 -	3.60 (1.32, 9.85)	4.77
$\frac{1}{102} (2) (2) (2) (2) (2) (2) (2) (2) (2) (2)$	himada (1) 2012		→ 9.82 (1.04, 92.82)	2.72	Shimada (2) 2012	3.02 (1.83,4.90)	4.00
$ \begin{array}{c} \mbox{match} 1 \mbox{match} 2 \mbox{match} $	nimada (2) 2012		4.47 (1.27, 15.69)	6.29	linuma(1) 2011	3.02 (1.03, 4.33)	10.20
$ \frac{320}{1000} (132, 251) + 350}{1000} (132, 251) + 350} (132, 25$	uma(1) 2011		3.84 (2.39, 6.17)	12.90	Uen 2008 -	2.94 (1.41, 6.12)	7.31
$ \begin{array}{c} ch 2006 \\ ch 2006 $	uma(2) 2011	-	3.20 (1.65, 6.22)	11.04	Allen-Mersh 2007	2.92 (1.07, 7.94)	4.80
$\frac{dathic 2005}{dstart = 72.9%, p = 0.001} \longrightarrow 0.51 (0.17, 151) 7.78 \\ 2.44 (1.16, 4.99) 53.26 \\ 0.108 1 2.44 (1.16, 4.99) 53.26 \\ 0.108 1 2.26 (1.16) 4.44 (1.16) 53.26 \\ 0.0108 1 2.26 (1.16) 4.44 (1.16) 53.26 \\ 0.0108 1 2.26 (1.16) 4.44 (1.16) 53.26 \\ 0.0108 1 2.26 (1.16) 4.44 (1.16) 53.26 \\ 0.0108 1 2.26 (1.16) 4.44 (1.16) 53.26 \\ 0.0108 1 2.26 (1.16) 4.44 (1.16) 53.26 \\ 0.0108 1 2.26 (1.16) 4.44 (1.16) 53.26 \\ 0.0108 1 2.26 (1.16) 4.44 (1.16) 53.26 \\ 0.0108 1 2.27 (1.06, 3.72) 4.77 \\ 0.108 1 2.27 (1.06, 3.72) 4.77 \\ 0.108 1 2.27 (1.06, 3.72) 4.77 \\ 0.108 1 2.27 (1.06, 3.72) 4.77 \\ 0.108 1 2.27 (1.06, 3.72) 4.77 \\ 0.108 1 2.27 (1.06, 3.72) 4.77 \\ 0.108 1 2.27 (1.06, 3.72) 4.77 \\ 0.108 1 2.27 (1.06, 3.72) 4.77 \\ 0.108 1 2.27 (1.06, 3.72) 4.77 \\ 0.108 1 2.27 (1.06, 3.72) 4.77 \\ 0.108 1 2.27 (1.06, 3.72) 4.77 \\ 0.108 1 2.27 (1.16, 3.72) 5.28 \\ 0.0249 1 4.01 1 \\ 0.01 1 2.27 (1.16, 0.16) 1 \\ 0.01 1 2.27 (1.16, 0.16) 1 \\ 0.01 1 2.27 (1.16, 0.16) 1 \\ 0.024 1 4.2 (1.16) 1.24 \\ 0.01 1 2.27 (1.16, 0.16) 1 \\ 0.01 1 2.27 ($	och 2006		6.40 (1.63, 25.16)	5.66	Koch 2006 -	2.40 (1.19, 4.85)	7.69
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	adahrio 2005	+ 1	0.51 (0.17, 1.51)	7.39	Sadahrio 2005	0.36 (0.12, 1.08)	4.14
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	ssa 2003	-	0.58 (0.19, 1.76)	7.26	Bessa 2003	0.64 (0.22, 1.86)	4.38
errall (1-squared = 53 7%, p = 0.08) 0 3.07 (2.05, 4.62) 100.00 2.58 (2.00, 3.32) 100.0 TE: Wayshawed = 0.0%, p = 0.08) 0 92.8 1001: Wayshawed = 24.0%, p = 0.080) 0 2.58 (2.00, 3.32) 100.0 Model (1)2013 0.0108 92.8 1001: Wayshawed = 0.0%, p = 0.080) 0 2.47 (102, 590) 7.68 Model (1)2013 0.0108 2.07 (0.58, 7.32) 4.77 4.07 (150, 1137) 7.34 Model (1)2013 0.07 (153, 1137) 7.34 1001: 1001: 1001: 2.47 (1102, 590) 7.68 Model (1)2013 0.37 (12.58, 12.74) 7.69 3.59 (2.26, 5.71) 3.55 3.55 (2.26, 5.71) 3.55 3.55 (2.26, 5.71) 3.56 (2.26, 5.71) 3.56 (2.26, 5.71) 3.56 (2.26, 1.14, 4.20) 100.02 3.50 (1.24, 2.24) 1.50 (1.12, 4.22) 2.15 (1.10, 4.24) 1.12 (1.10, 4.34) 1.12 (1.10, 4.34) 1.12 (1.10, 4.34) 1.12 (1.10, 4.34) 1.12 (1.10, 4.34) 1.12 (1.10, 4.34) 1.12 (1.10, 4.34) 1.12 (1.10, 4.34) 1.12 (1.10, 4.34) 1.12 (1.10, 4.34) 1.12 (1.10, 4.34) 1.12 (1.10, 4.34) 1.12 (1.10, 4.34) 1.12 (1.10, 4.34) 1.12 (1.10, 4.34) 1.12 (1.10, 4.34) <td>btotal (I-squared = 72.9%, p = 0.001)</td> <td>0</td> <td>2.44 (1.19, 4.99)</td> <td>53.26</td> <td>Subtotal (I-squared = 55.9%, p = 0.016)</td> <td>2.41 (0.72, 8.10) 2.23 (1.50, 3.29)</td> <td>3.57 62.42</td>	btotal (I-squared = 72.9%, p = 0.001)	0	2.44 (1.19, 4.99)	53.26	Subtotal (I-squared = 55.9%, p = 0.016)	2.41 (0.72, 8.10) 2.23 (1.50, 3.29)	3.57 62.42
$\frac{1}{12} (12) (12) (12) (12) (12) (12) (12) (12)$	verall (I-squared = 55.7%, p = 0.008)	0	3.07 (2.05, 4.62)	100.00	Overall (I-squared = 34.0% p = 0.085)	2 58 (2 00 3 32)	100.00
$\frac{1}{12} \frac{1}{12} \frac$	TE: Weights are from random effects analysis				NOTE: Weights are from random effects analysis	2.00 (2.00, 0.02)	100.00
$\frac{d^{2} C}{p^{2}} \frac{d^{2} C}$.0108	1	92.8		.0249 1	40.1	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$							
Bood (f) 2013 (skort(1)2013 (skort(1)2013) (skort	^{idy} C		HR (95% CI)	% Weight	ID Study	HR (95% CI)	% Weigh
the definition of the definit		1			Mithaut		
(11) 2013 2.07 (0.58, 7.32) 4.77 Violobori (2013) 4.60 (1.34, 16.36) 4.90 Nobori (2013) 4.60 (1.34, 16.36) 4.90 Mindad (1) 2012 3.21 (1.44, 7.46) 11.33 Janual (2.1) 2011 3.21 (1.44, 7.46) 11.33 Jatobal (1) 2012 3.50 (1.24, 12.47) 5.79 Jatobal (1) 2013 3.76 (1.25, 12.47) 5.79 Jatobal (1) 2013 3.76 (1.25, 12.47) 5.79 Jatobal (1-squared = 0.0%, p = 0.879) 3.59 (2.86, 5.71) 35.65 Nakoon(202013 0.52 (0.06, 4.66) 1.61 Lig (2) 2012 0.52 (0.06, 4.66) 1.61 Lig (2) 2013 0.51 (0.11, 2.42) 2.31 Vaboori (2) 2013 0.51 (0.11, 2.42) 2.31 Jatobal (1-squared = 2.0 %, p = 0.851) 3.15 (2.36, 4.15) 100.00 Jatobal (1-squared = 2.1%, p = 0.265) 3.15 (2.36, 4.15) 100.00 Jet III 1.76 3.15 (2.36, 4.15) 100.00 Jatobal (1-squared = 0.0%, p = 0.550) 3.15 (2.36, 4.15) 100.00 Jatobal (1-squared = 0.0%, p = 0.550) 3.27 (1.42, 4.63) 2.30 Jatobal (1-squared = 0.0%, p =	thout				Without	0.17.0.00.000	7.00
Aldoor (1) 2013 4 07 (150, 11.57) 7.34 4 07 (150, 11.57) 7.34 Mobion (2) 2013 Mage 11.90 1.52 1.52 1.52 Immade (1) 2012 Mage 11.90 1.52 1.57 3.56 2.57 Marcel 10 (1) 2013 3.59 (12.6, 12.47) 5.79 3.56 3.59 2.26, 5.71 3.56 Skoon (2) 2013 0.52 (0.66 ke1 1.61 1.14 1.16 1.14 1.14 1.14 1.14 1.14 1.14 1.14 1.14 1.14 1.14 1.14 1.14 1.14 1.14 1.16 1.14 1.14 1.14 1.16 1.14 1.14 1.16 1.14 1.14 1.16	u (1) 2013 -	•	2.07 (0.58, 7.32)	4.77	Liu (1) 2013	2.47 (1.02, 5.96)	7.08
Alcohor(3)2013 4 60 (1.34, 16.36) 4.90 Mindad (1) 2012 3.20 (1.44, 7.40) 11.33 Juma(1-1) 2011 3.21 (1.44, 7.40) 11.33 Juma(2) 12011 3.50 (2.26, 5.71) 3.56 (5.71) Jstop (2) 2013 0.52 (0.06, 4.68) 1.61 J(2) 2013 0.52 (0.06, 4.68) 1.61 J(2) 2013 0.52 (0.06, 4.68) 1.61 Jstop (2) 2013 0.52 (0.06, 4.68) 1.61 J(2) 2013 0.52 (0.06, 4.68) 1.61 J(2) 2013 0.52 (0.06, 4.68) 1.61 Jstop (2) 2013 0.51 (0.11, 2.42) 2.31 Mind(1) 2013 4.47 (1.54, 15.95) 3.16 (2.30, 12.01) Juma(2) 2011 2.62 (1.14, 4.20) 1.02 Juma(2) 2021 3.15 (2.38, 4.15) 100.00 Juma(2) 2021 3.16 (2.34, 4.52) 2.33 Juma(2) 2021 3.17 (1.25, 1.57) 7.12 Juma(2) 2021 3.17 (1.25, 1.5.7) 7.12	okobori(1)2013		4.07 (1.50, 11.57)	7.34	Yokobori (1) 2013	2.73 (1.16, 6.24)	7.80
$ \frac{1}{10} $	kobori(3)2013		4.60 (1.34, 16.36)	4.90	Yokobori (3) 2013 -	4.46 (1.73, 11.62)	6.08
amp(1-1)2011 a.32 (1,1.4,7,46) 11.33 minuma(2-1)2011 a.35 (1.66,674) 11.23 btolal (l-squared = 0.0%, p = 0.879) a.35 (1.26, 5.71) 3.56 (2.6, 5.71) skDOP CT 0.52 (0.06, 4.68) 1.61 (log) 2013 a.57 (1.42, 4.43) 2.19 (1.10, 4.34) kbobil(2)2013 a.57 (1.42, 4.43) 2.19 (1.10, 4.34) minuma(2-1)2011 a.57 (1.42, 4.43) 2.19 (1.10, 4.34) minuma(2-1)2011 a.57 (1.42, 4.43) 1.9.2 minuma(2-1)2011 a.57 (1.44, 4.40) 1.9.2 minuma(2-1)2011 a.0.563 1.78 0.0563 1.78 0.248 40.3 dvir E HR (95% C1) % minuma(1-1)2011 a.0.77 (0.13, 4.62) 2.33 (1/1)2013 0.77 (0.13, 4.62) 2.33 vir Ways are two mode mitters anayes a.0.75 (1.15, 2.47) 5.82 minuma	imada (1) 2012	++	→ 9.82 (1.99, 177.57)	1.52	Shimada (1) 2012 -	3.60 (1.45, 10.86)	5.46
amg2-1/2011 3.75 (125, 12.47) 5.79 btobal 3.75 (125, 12.47) 5.79 stop 3.39 (22.6, 5.71) 3.56 stop 0.52 (0.06, 4.68) 1.61 (12) 2013 0.52 (0.16, 4.68) 1.61 voltop 2.57 (1.42, 4.53) 21.94 yokoon(4) 2013 7.01 (2.80, 1941) 8.18 ama(2-2) 2011 2.57 (1.42, 4.53) 21.94 yokoon(4) 2013 2.57 (1.44, 4.50) 1.60 ama(2-2) 2011 2.47 (1.06, 6.25) 9.74 bital (1-squared = 0.0%, p = 0.651) 3.15 (2.38, 4.15) 100.00 reg II 0.0063 1 178 0.0248 1 40.3 voltop (1) 2013 407 (1.50, 11.57) 7.12 Voltop (1.157) 7.12 Voltop (1.157) 2.35 (1.44, 7.43) 1.60 voltop (1) 2013 407 (1.49, 1.157) 7.12 Voltop (1.157) 0.59 3.03 (2.40, 3.83) 100.00 voltop (1.12, 2013 0.0248 1 40.3 0.0248 1 40.3 voltop (1.12, 2014) 3.15 (2.38, 4.15) 100.00 0.0248 1 <	uma(1-1) 2011		3.21 (1.44 7.46)	11.33	linuma(1-1) 2011 -	3.35 (1.66, 6.74)	11.24
bitslal (4-squared = 0.0%, p = 0.879) 3.39 (22.6, 5.71) 35.65 st-OP CT (2) 2013 0.52 (0.06, 4.68) 1.61 stoor(2) 2013 0.52 (0.06, 4.68) 1.61 stoor(2) 2013 0.52 (0.06, 4.68) 1.61 stoor(2) 2013 0.51 (0.11, 2.42) 2.31 stoor(2) 2013 0.51 (0.11, 2.42) 2.31 stoor(2) 2013 4.47 (154, 1.859) 4.66 stoor(4) 2011 2.26 (1.16, 4.47) 1.02 stoor(4) 2013 2.47 (1.16, 6.25) 9.74 stoor(4) 2013 3.15 (2.34, 4.15) 100.00 stoor(1) 2013 0.0563 1 178 stoor(1) 2013 0.07 (0.13, 4.62) 2.33 4.03 stoor(1) 2013 4.07 (1.50, 11.57) 7.12 0.58 (1.86, 6.24) 7.19 stoor(1) 2013 4.07 (1.50, 11.57) 7.12 0.58 (1.86, 6.24) 7.19 stoor(1) 2013 4.07 (1.50, 11.57) 7.12 0.58 (1.86, 6.74) 0.248 40.3 stoor(1) 2013 0.77 (0.13, 4.62) 2.33 1.02 0.59 (0.13, 2.01) 2.71 stoor(1) 2013 4.07 (1.50, 11.57) 7.12 0.59	uma(2-1) 2011		3.75 (1.25 12.47)	5.79	linuma(2-1) 2011 -	3.10 (1.33, 7.24)	7.69
structure (required = 0.0%, p = 0.383) 3.19 (2.26, 4.50) 46.18 stdop CT (2) 2013 0.52 (0.06, 4.68) 1.61 stdop CT (2) 2013 0.52 (0.06, 4.68) 1.61 stdop CT (2) 2013 2.57 (1.42, 4.63) 21.94 mard (2) 2012 4.47 (1.54, 1.859) 4.61 mard (2) 2013 2.26 (1.16, 4.20) 10.02 mard (2) 2011 2.247 (1.06, 6.25) 9.74 bitchall (required = 2.0%, p = 0.285) 3.15 (2.38, 4.15) 100.00 reg II (1.2013 0.0563 1 178 obsord (1.2013 0.077 (0.13, 4.62) 2.33 100.00 reg III (1.2013 0.077 (0.13, 4.62) 2.33 .00563 1 178 0.248 40.3 bitorial (required = 0.0%, p = 0.285) 0.03 (2.20, 3.43) 100.00 reg III 0.0248 40.3 0.0248 40.3 bitorial (required = 0.0%, p = 0.599) 3.03 (2.40, 3.83) 100.00 2.277 (1.16, 6.23) 2.271 (1.16, 4.24) 1.282 (1.24, 7.16) reg III 1.2011 0.0248 1 40.3 2.272 (1.16, 6.24) 7.19	htotal (I-squared = 0.0% n = 0.870)	0	3 59 (2 26 5 71)	35.65	Lloyd 2006	3.03 (0.23, 40.33)	0.83
94:OP CT (2) 2013 tobor(2) 2013 tobor(2) 2013 made (2) 2011 mand (2) 2011 mand (2) 2011 mand (2) 2011 mand (2) 2011 total (1-squared = 20.1%, p = 0.268) 0.51 (0.11, 2.42) 2.57 (1.42, 4.63) 2.257 (1.42, 4.63) 2.267 (1.16, 6.25) 2.267 (1.16, 6.25) 0.247 (1.06, 6.25) 0.247 (1.06, 6.25) 0.256 (1.16, 6.47) Post-OP CT Liu (2) 2013 Yokobor (2) 2013 Yokobor (2) 2013 Yokobor (2) 2013 Yokobor (2) 2013 Total (1-squared = 20.0%, p = 0.267) 0.51 (0.11, 2.42) 2.19 (1.10, 4.34) 1.172 3.35 (1.42, 1.02, 4.58) adv Erall (1-squared = 0.0%, p = 0.651) 0.00563 3.15 (2.38, 4.15) 100.00 Yokobor (4) 2013 Yokobor (4) 2013 Notobor (4) 2	11-340area - 0.070, p = 0.079)	Y	3.55 (2.20, 3.11)	33.03	Subtotal (I-squared = 0.0%, p = 0.985)	3.19 (2.26, 4.50)	46.18
(µ2) 2013 0.52 (0.06. 4.69) 1.61 0.52 (0.06. 4.69) 1.61 0.52 (0.06. 4.69) 1.61 0.52 (0.06. 4.69) 1.61 0.52 (0.06. 4.69) 1.61 0.52 (0.06. 4.69) 1.61 0.52 (0.06. 4.69) 1.61 0.52 (0.07. 4.62.5) 2.57 (1.12. 4.2) 0.016 (1.12. 4.2) 2.51 (1.10. 4.30) 0.017 (1.10. 6.23) 1.72 0.016 (1.10. 6.23) 2.74 (1.10. 6.25) 0.016 (1.10. 6.23) 1.72 0.016 (1.10. 4.2) 2.26 (1.14. 4.20) 0.016 (1.10. 4.20) 2.26 (1.14. 4.20) 0.016 (1.10. 4.62) 2.23 (1.12. 4.61) 0.016 (1.10. 4.62) 2.23 (1.12. 4.61) 0.016 (1.10. 4.62) 2.33 0.016 (1.10. 4.62) 2.33 0.016 (1.10. 4.62) 2.33 0.016 (1.10. 4.62) 2.33 0.017 (1.13. 4.62) 2.33 0.018 (1.10. 4.62) 2.33 0.018 (1.10. 4.62) 3.03 (1.10. 4.62) 1.101 (1.2013) 0.01 (1.3.462) 2.33 0.018 (1.101. 4.62) 0.33 (1.10. 4.62) 1.101 (1.13.462) <	ost-OP CT				Post-OP CT		
kabobic 2.57 (1.42, 4.63) 21.94 7,01 (2.80, 19.41) 7,01 (2.80, 19.41) 11.72 Vackobic (4) (2013 4.77 (1.54, 18.55) 4.86 umal(2) 2011 2.62 (1.14, 4.20) 11.72 Vackobic (4) 2013 3.50 (1.42, 10.51) 5.50 umal(2-2) 2011 2.477 (1.06, 6.25) 9.74 Verall (1-squared = 2.2.1%, p = 0.651) 3.15 (2.38, 4.15) 100.00 .00563 1 176 .00563 1 176 .00563 1 176 .00563 0.77 (0.13, 4.62) 2.33 .00163 1.172 .077 (0.13, 4.62) 2.33 .0026 0.77 (0.13, 4.62) 2.33 .011 2.011 .077 (0.13, 4.62) 2.33 .012 1.011 .077 (0.13, 4.62) 2.33 .012 1.011 .077 (0.13, 4.62) 2.33 .012 1.011 .077 (0.13, 4.62) 2.33 .012 1.011 .077 (0.13, 4.62) 2.33 .012 1.011 .077 (0.13, 4.62) 2.33 .012 1.011 .077 (0.13, 4.62) 2.33 .017 1.23 1.172 .077 (0.13, 4.62	u (2) 2013	+	0.52 (0.06, 4.68)	1.61	Liu (2) 2013	0.51 (0.11, 2.42)	2.31
Actobaci(2)2013 7.01 (2.80, 19.41) 8.18 Yotobaci(2)2013 4.47 (12.54, 18.95) 4.68 uma(2-2) 2011 2.47 (10.6, 6.25) 9.74 whotail (1-squared = 2.0.%, p = 0.651) 2.46 (15.6, 4.47) 64.35 verail (1-squared = 2.0.%, p = 0.651) 3.15 (2.38, 4.15) 100.00 re: Weight 3.15 (2.38, 4.15) 100.00 re: Weight 0.0563 1 178 udy E HR (95% C1) Weight 0.077 (0.13, 4.62) 2.33 whobori (3) 2013 4.07 (1.50, 11.57) 7.12 Study F HR (95% C1) weight are from random effects analysis 0.277 (0.13, 4.62) 2.33 4.07 (1.50, 11.57) 7.12 whobori (3) 2013 4.07 (1.50, 11.57) 7.12 Stage II 1.01 (1.33, 7.24) 7.09 wraid-1/ 2011 3.72 (2.26, 5.65) 3.62 (1.44, 7.16.25) 3.60 (1.45, 1.626) 2.77 (1.96, 6.27) wraid-1/ 2011 3.75 (1.25, 1.247) 5.62 3.60 (1.45, 1.626) 3.77 (1.26, 1.64) 3.75 (1.25, 1.247) wraid-1/ 2011 3.75 (1.25, 1.247) 5.82 1.37 (0.26, 5.78) 2.93	okobori(2)2013		2.57 (1.42, 4.63)	21.94	Yokobori (2) 2013	2 19 (1 10, 4 34)	11.72
immada (2) 2012 uma(2-2) 2011 uma(2-2) 2011 uma(2-2) 2011 uma(2-2) 2011 uma(2-2) 2011 uma(2-2) 2011 uma(2-2) 2011 uma(2-2) 2011 uma(2-2) 2011 immada (2) 2012 immada (2) 2011 immada (2) 2013 immada (2) 2013 immada (2) 2013 immada (2) 2013 immada (2) 2013 immada (2) 2012 immada (2) 2012	okobori(4)2013		7.01 (2.80, 19.41)	8.18	Yokobori (4) 2013	4.37 (2.15, 8.94)	10.87
uma(2:2) 2011 2.62 (1:1.4, 4.20) 18.02 uma(2:2) 2011 2.96 (1:5.6, 4.47) 64.35 uma(2:2) 2011 2.96 (1:5.6, 4.47) 64.35 verail (1-squared = 0.0%, p = 0.651) 3.15 (2:3.8, 4.15) 100.00 TE: Weights are from random effects analysis 0.0563 1 178 udy E HR (95% CI) % (1) 2013 0.77 (0:13, 4.62) 2.33 vkobori (1) 2013 0.50 (0:13, 1:57) 7.12 vkobori (1) 2013 3.75 (1:25, 1:2.47) 5.82 vkobori (1) 2013 3.75 (1:2.51, 2:47) 5.82 vkobori (4) 2013 1.37 (0:28, 6:78) 2.93 vkobori (4) 2013 1.37 (0:28, 6:78) 2.93 vkobori (4) 2013 2.57 (1:42, 4:53) 2.128 vkobori (4) 2013 2.57 (1:42, 4:53) 2.128	himada (2) 2012		4.47 (1.54, 18.95)	4.86	Shimada (2) 2012	3 50 (1 42 10 54)	5 50
umag(2-2) 2011 (b)total (1-squared = 22.1%, p = 0.268) 2.47 (10.6 6.25) 9.74 2.96 (1.96, 4.47) 64.35 verail (1-squared = 20.0%, p = 0.217) 3.15 (2.38, 4.15) 100.00 Tre: Wagits are trem random effects analysis 3.15 (2.38, 4.15) 100.00 udy E HR (95% CI) Weight age II (1) (2013 wobori (3) 2013 whobri (3) 2013 whobri (2) 2011 weight (1) 2012 whobri (2) 2013 whobri (4) 2013 whobri (4) 2013 whothri (1) 2012 winanda (2) 2011 winanda (2) 2011 winan	uma(1-2) 2011		2.62 (1.14, 4.20)	18.02	linuma(1-2) 2011	3 26 (1 74 6 25)	13 50
bitotal (i-squared = 22.1%, p = 0.268) 2.96 (1.96, 4.47) 64.35 verail (i-squared = 20.0%, p = 0.651) 3.15 (2.38, 4.15) 100.00 TE: Weights are from random effects analysis 0.0563 1 178 udy E % Weight 0.077 (0.13, 4.62) 2.33 1(1) 2013 0.077 (0.13, 4.62) 2.33 0.077 (0.15, 4.62) 2.33 verail (1-squared = 0.0%, p = 0.59) 0.570 (1.57) 7.12 Yelkobri (1/2013 0.500 (0.13, 2.01) 2.71 wabori (1/2013 4.60 (1.34, 16.36) 4.75 Yelkobri (1/2013 0.500 (0.13, 2.01) 2.71 windic1/2011 3.27 (1.26, 1.24) 5.61 Stimidad (1/2013 0.500 (1.3, 2.01) 2.71 verail (1-squared = 0.0%, p = 0.599) 3.72 (2.86, 5.85) 3.62 3.72 (2.86, 5.85) 3.62 age III (2) (2) 13 1.37 (0.28, 6.78) 2.93 1.37 (0.28, 6.78) 2.93 verail (1-squared = 0.0%, p = 0.599) 3.20 (2.44, 4.21) 1.78 1.83 (0.61, 5.52) 4.20 verail (1-squared = 0.0%, p = 0.599) 3.72 (2.86, 5.85) 3.62.41 1.18 1.83 (0.61, 5.52) 4.20 verail (1-squared = 0.0%, p = 0.5	uma(2-2) 2011		2.47 (1.06, 6.25)	9.74	linuma(2-2) 2011	2.97 (1.44, 6.40)	9.92
werall (i-squared = 0.0%, p = 0.651) 3.15 (2.38, 4.15) 100.00 TE: Weights are from random effects analysis 0.0563 1 176 udy E HR (95% CI) %6 (1) 2013 0.077 (0.13, 4.62) 2.33 (1) 2013 0.077 (0.13, 4.62) 2.33 (1) 2013 0.077 (0.13, 4.62) 2.33 (1) 2013 0.077 (0.13, 4.62) 2.33 (1) 2013 4.07 (1.50, 11.57) 7.12 (1) 2013 4.07 (1.50, 11.57) 7.12 (1) 2013 3.75 (1.25, 12.47) 5.62 (1) 2013 3.75 (1.25, 12.47) 5.62 (1) 2013 3.75 (1.25, 12.47) 5.62 (1) 2013 3.75 (1.26, 5.85) 3.62.44 (1) 2013 3.75 (1.26, 2.47) 5.62 (2) 2013 1.37 (0.28, 6.78) 2.93 (2) 2013 2.57 (1.42, 4.63) 2.12.8 (1) 2013 2.57 (1.42, 6.12) 1.38 (0.61, 5.52) (2) 2013 4.47 (1.54, 18.95) 4.71 (1) 2013 2.97 (1.44, 6.40) 1.48 (2.2) 12.3 (1) 2013 2.97 (1.44, 6.40) 1.57	ubtotal (I-squared = 22.1%, p = 0.268)	\diamond	2.96 (1.96, 4.47)	64.35	Subtotal (I-squared = 29.0%, p = 0.217)	2.83 (1.92, 4.19)	53.82
Strice	verall (Leavared = 0.0%, p = 0.651)		2 45 (2 28 4 45)	100.00		2 02 (2 40 2 92)	100.00
Non-the region and rotation index analysis Image is an index index analysis Image is an index index analysis udy E HR (95% Cl) %6 y(1) 2013 0.77 (0.13, 4.62) 2.33 wkobori (1) 2013 0.77 (0.13, 4.62) 2.33 wkobori (1) 2013 4.60 (1.34, 16.36) 4.75 y(1) 2011 982 (1.99, 177.57) 1.47 uma(1-1) 2011 3.25 (1.14, 7.46) 10.98 uma(1-2) 2011 3.25 (1.25, 12.47) 5.62 ibtobal (I-squared = 0.0%, p = 0.599) 3.72 (2.36, 5.85) 36.24 age III 1.37 (0.28, 6.78) 2.93 (2) 2013 (1.42, 16.39) 4.71 wkobori (2) 2013 (1.47, 1.68, 5.2) 2.18 wkobori (2) 2013 (2.20, 1.14, 2.00) 1.74 uma(2-2) 2011 (1.42, 0.66, 78) 2.93 uma(2-2) 2011 2.47 (1.06, 6.25) 9.44 Uma(2-2) 2011 2.94 (2.09, 4.14) 63.76 uma	TE: Weights are from random offests analysis	Y	3.15 (2.36, 4.15)	100.00	Overall (I-squared = 0.0%, p = 0.769)	3.03 (2.40, 3.83)	100.00
$\frac{dy}{E} + \frac{w}{HR(95\% Cl)} + \frac{w}{Weight} + \frac{w}{HR(95\% Cl)} + \frac{w}{HR(95\% Cl)} + \frac{w}{Weight} + \frac{w}{HR(95\% Cl)} + \frac{w}{HR(95\% Cl)} + \frac{w}{Weight} + \frac{w}{HR(95\% Cl)} + \frac{w}{HR(95\% C$	IL: weights are from random effects analysis	1	178		NOTE: Weights are from random effects analysis 0248 1	40.3	
ddy HR (95% Cl) Weight Study F HR (95% Cl) Weight age II 0.77 (0.13, 4.62) 2.33 0.77 (0.13, 4.62) 2.33 0.77 (0.13, 4.62) 2.33 kobori (1) 2013 0.77 (0.13, 4.62) 2.33 4.07 (1.50, 11.57) 7.12 Yokobori (1) 2013 0.50 (0.13, 2.01) 2.71 mada (1) 2012 9.82 (1.99, 177.57) 1.47 Shimada (1) 2012 3.60 (1.45, 10.86) 5.03 arma(1-1) 2011 3.75 (1.25, 12.47) 5.62 Inuma(2-1) 2011 3.360 (1.45, 10.86) 5.03 total (1-squared = 0.0%, p = 0.599) 3.72 (2.36, 5.85) 36.24 Inuma(2-1) 2011 3.37 (1.28, 0.87, 2.93 2.577 (1.42, 4.63) 21.28 kobori (2) 2013 1.37 (0.28, 6.78) 2.93 Yokobori (2) 2013 2.19 (1.10, 4.34) 10.83 kobori (2) 2013 1.37 (0.28, 6.78) 2.93 Yokobori (2) 2013 3.26 (1.74, 6.25) 2.40 mra(2-2) 2011 2.62 (1.14, 4.20) 17.48 Yokobori (2) 2013 3.26 (1.74, 6.25) 2.40 mra(2-2) 2011 2.62 (1.14, 4.20) 17.48 Inuma(2-2) 2011 3.26 (1.42, 0.53) 3.26 (1.44, 6.25) 2.40 <	.00000					40.0	
age II (1) 2013 (x0bori (1) 2013 (x0bori (1) 2013 (x0bori (1) 2013 (x0bori (1) 2013 (x0bori (1) 2012 uma(1-1) 2011 (x12) 2011 (x12) 2011 (x12) 2011 (x12) 2013 (x12) 2013 (x12) 2013 (x12) 2013 (x12) 2014 (x12) 2011 (x12) 2013 (x12) 2014 (x13) 2014 (x14) 202 (x14) 4.20 (x14) 4.2	^{idy}		HR (95% CI)	% Weight	Study ID	HR (95% CI)	% Weigh
(1) 2013 0.77 (0.13, 4.62) 2.33 Liu (1) 2013 0.50 (0.13, 2.01) 2.71 (xobori (3) 2013 4.60 (1.41, 15.67) 7.12 Yokobori (3) 2013 2.73 (1.16, 6.24) 7.19 (mada (1) 2012 9.82 (1.99, 177.57) 1.47 Shimada (1) 2012 3.60 (1.45, 10.86) 5.03 (mada (1) 2011 3.21 (1.44, 7.46) 10.98 linuma(1-1) 2011 3.35 (1.66, 6.74) 10.37 (mada (1) 2012 3.75 (1.25, 12.47) 5.62 linuma(2-1) 2011 3.35 (1.66, 6.74) 10.37 (1) 2013 6.40 (2.03, 4.00) 3.96 Koch 2006 2.04 (1.30, 5.30) 10.31 (2) 2013 5.77 (1.28, 0.78) 2.93 Liu (2) 2013 2.77 (1.90, 4.02) 48.31 (2) 2013 1.37 (0.28, 6.78) 2.93 Subtotal (I-squared = 22.4%, p = 0.258) 2.77 (1.90, 4.02) 48.31 (2) 2013 2.057 (1.42, 4.63) 21.28 Yokobori (2) 2013 2.19 (1.10, 4.34) 10.80 (2) 2013 1.37 (0.28, 6.78) 2.93 Liu (2) 2013 2.19 (1.10, 4.34) 10.80 (2) 2013 1.37 (0.28, 6.78) 2.93 Yokobori (2) 2013 2.97 (1.44, 6.40) 9.15 <	age II	1			Stage II	1	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	(1) 2013		0.77 (0.13, 4.62)	2.33	Liu (1) 2013	0.50 (0.13, 2.01)	2.71
A 60 (13, 41, 16, 36, 175) Yokobori (3, 2013) A 10 (110, 0.24) A 116 (1.7, 116, 2) 5.61 imada (1) 2012 A 9.82 (1.99, 177, 57) 1.47 Shimada (1) 2012 A 64 (1.7, 31, 16, 2) 5.61 imara(2-1) 2011 3.25 (1.44, 7.46) 10.98 Iinuma(1-1) 2011 3.35 (1.66, 6.74) 10.37 rma(2-1) 2011 3.75 (1.25, 12.47) 5.62 Iinuma(1-1) 2011 3.35 (1.66, 6.74) 10.37 rma(2-1) 2011 6.40 (2.20, 34.00) 3.96 Koch 2006 2.40 (1.30, 5.30) 10.31 ge III (2) 2013 1.37 (0.28, 6.78) 2.93 Subtotal (I-squared = 22.4%, p = 0.258) 2.77 (190, 4.02) 48.31 imada (2) 2012 1.37 (0.28, 6.78) 2.93 Yokobori (2) 2013 2.19 (1.10, 4.34) 10.80 imada (2) 2012 1.37 (0.28, 6.78) 2.93 Yokobori (2) 2013 2.19 (1.10, 4.34) 10.80 imada (2) 2012 1.37 (0.28, 6.78) 2.93 Yokobori (2) 2013 3.50 (1.42, 1.05.4) 5.05 imada (2) 2012 1.476 2.47 (1.10, 6.25) 4.71 Shimada (2) 2012 3.50 (1.42, 1.05.4) 5.08 imada (2) 2011 2.46 (1.73, 11.43.6) 3.20 (2.44, 4.21) 100.0	kobori (1) 2013		4.07 (1.50 11.57)	7.12	Yokobori (1) 2013	2 73 (1 16 6 24)	7.19
mada (1) 2012 mma(1-1) 2011 9.82 (1.99, 177, 57) 1.47 Shimada (1) 2012 ma(2-1) 2011 3.21 (1.44, 7.46) 10.88 linuma(1-1) 2011 ma(2-1) 2011 3.75 (1.25, 12.47) 5.62 linuma(2-1) 2011 ma(2-1) 2011 3.75 (1.25, 12.47) 5.62 linuma(2-1) 2011 shotodi (I-squared = 0.0%, p = 0.599) 3.72 (2.36, 5.85) 36.24 Subtotal (I-squared = 22.4%, p = 0.258) ge III 1.37 (0.28, 6.78) 2.93 Subtotal (I-squared = 22.4%, p = 0.258) 2.77 (1.90, 4.02) ge III 2.557 (1.42, 4.53) 21.28 Yokobori (2) 2013 2.95 (1.14, 4.20) 1.83 (0.61, 5.52) 4.20 (2) 2013 7.01 (2.80, 19.41) 7.93 Yokobori (4) 2013 3.50 (1.42, 10.54) 5.08 ma(2-2) 2011 2.66 (1.14, 4.20) 17.48 Inuma(2-2) 2011 3.50 (1.42, 10.54) 5.08 ma(2-2) 2011 2.94 (2.09, 4.14) 63.76 Subtotal (I-squared = 0.0%, p = 0.560) 2.90 (2.32, 3.64) 100.00 Overall (I-squared = 0.0%, p = 0.560) 2.90 (2.32, 3.64) 100.00 Overall (I-squared = 0.0%, p = 0.560) 2.90 (2.32, 3.64) 100.00 Overall (I-squared	kobori (3) 2013		4.60 (1.34 16.36)	4.75	Yokobori (3) 2013	446 (1 73 11 62)	5.61
ma(1-1) 2011 3.21 (1.44, 7.46) 10.98 Iinuma(1-1) 2011 ima(2-1) 2011 3.75 (1.25, 12.47) 5.62 Iinuma(2-1) 2011 ch 2006 6.40 (2.20, 34.00) 3.96 Koch 2006 obtat (I-squared = 0.0%, p = 0.599) 3.72 (2.36, 5.85) 36.24 Subtotal (I-squared = 22.4%, p = 0.258) ge III 1.37 (0.28, 6.78) 2.93 Subtotal (I-squared = 22.4%, p = 0.258) 2.40 (1.30, 5.30) ge III 1.37 (0.28, 6.78) 2.93 Subtotal (I-squared = 22.4%, p = 0.258) 2.77 (1.90, 4.02) ge III 1.37 (0.28, 6.78) 2.93 Subtotal (I-squared = 22.4%, p = 0.258) 2.77 (1.90, 4.02) ge III 1.37 (0.28, 6.78) 2.93 Subtotal (I-squared = 22.4%, p = 0.258) 2.40 (1.30, 5.30) 10.31 ge III 1.37 (0.28, 6.78) 2.93 Subtotal (I-squared = 22.4%, p = 0.258) 2.40 (1.30, 5.30) 10.31 ge III 1.37 (0.28, 6.78) 2.93 1.53 (0.61, 5.52) 4.20 ge III 1.37 (0.28, 6.78) 2.93 1.53 (0.61, 5.52) 4.20 ge III 1.37 (0.28, 6.78) 2.93 1.53 (0.61, 5.52) 4.20 ge III 2.2011 1.33 (0.61,	mada (1) 2012		9.82 (1.99, 177 57)	1.47	Shimada (1) 2012	3.60 (1.45, 10.86)	5.03
ma(2-1) 2011 3.75 (1.25, 12.47) 5.62 linuma(2-1) 2011 3.10 (1.33, 7.24) 7.09 ch 2006 6.40 (2.20, 34.00) 3.96 Koch 2006 2.40 (1.30, 5.30) 10.31 ge III (2) 2013 1.37 (0.28, 6.78) 2.93 Subtotal (I-squared = 22.4%, p = 0.258) 2.77 (1.90, 4.02) 48.31 (2) 2013 1.37 (0.28, 6.78) 2.93 Liu (2) 2013 2.19 (1.10, 4.34) 10.80 kobori (2) 2013 7.01 (2.80, 19.41) 7.93 Yokobori (2) 2013 4.37 (2.15, 4.54) 10.42 mada (2) 2012 4.47 (1.54, 18.95) 4.71 Shimada (2) 2012 3.50 (1.42, 1.55) 10.42 ima(2-2) 2011 2.62 (1.14, 4.20) 17.48 linuma(2-2) 2011 3.26 (1.74, 6.25) 12.45 ibtotal (I-squared = 0.0%, p = 0.432) 2.94 (2.09, 4.14) 63.76 Subtotal (I-squared = 0.0%, p = 0.560) 2.90 (2.32, 3.64) 10.00 NOTE: Weights are from random effects analysis 17.8 NOTE: Weights are from random effects analysis 11.6	ma(1-1) 2011	+	3.21 (1.44. 7.46)	10.98	linuma(1-1) 2011	3.35 (1.66, 6.74)	10.37
ch 2006 6.40 (2.20, 34.00) 3.96 Koch 2006 2.40 (1.30, 5.20) 0.51 btotal (I-squared = 0.0%, p = 0.599) 3.72 (2.36, 5.85) 36.24 Subtotal (I-squared = 22.4%, p = 0.258) 2.77 (1.90, 4.02) 48.31 (2) 2013 1.37 (0.28, 6.78) 2.93 Liu (2) 2013 2.19 (1.10, 4.34) 10.80 (kobori (4) 2013 7.01 (2.80, 19.41) 7.93 Yokobori (4) 2013 2.19 (1.10, 4.34) 10.80 imada (2) 2012 4.47 (1.54, 18.95) 4.71 Shimada (2) 2012 3.50 (1.42, 10.54) 5.08 imada (2) 2011 2.62 (1.14, 4.20) 17.48 linuma(1-2) 2011 3.50 (1.42, 10.54) 5.08 imada (2) 2012 2.94 (2.09, 4.14) 63.76 Subtotal (I-squared = 0.0%, p = 0.560) 2.90 (2.32, 3.64) 100.00 Te: Weights are from random effects analysis 00561 1 178 0051 1 1	(2-1) 2011		3.75 (1.25, 12.47)	5.62	linuma(2-1) 2011 -	3.10 (1.33.7.24)	7.09
btotal (I-squared = 0.0%, p = 0.599) 3.72 (2.36, 5.85) 36.24 Subtotal (I-squared = 22.4%, p = 0.258) 2.77 (1.90, 4.02) 48.31 age III 1.37 (0.28, 6.78) 2.93 Liu (2) 2013 2.19 (1.10, 4.34) 10.80 kobori (2) 2013 7.01 (2.80, 19.41) 7.93 Yokobori (2) 2013 2.19 (1.10, 4.34) 10.80 watch 2 (1.22, 2012 4.47 (1.54, 18.95) 4.71 Shimada (2) 2012 4.37 (1.25, 8.94) 10.02 uma(2-2) 2011 2.62 (1.14, 4.20) 17.48 Ilnuma(1-2) 2011 3.20 (1.42, 10.54) 5.08 btotal (I-squared = 0.0%, p = 0.432) 2.94 (1.06, 6.25) 9.44 Ilnuma(1-2) 2011 3.20 (2.44, 4.21) 100.00 TE: Weights are from random effects analysis 00561 1 178 0061 1 11.6	och 2006	÷	6.40 (2.20, 34.00)	3.96	Koch 2006 -	2.40 (1.30, 5.30)	10.31
age III Stage III (2) 2013 1.37 (0.28, 6.78) 2.93 kobori (2) 2013 2.57 (1.42, 4.63) 21.28 kobori (2) 2013 7.01 (2.80, 19.41) 7.93 yokobori (2) 2012 4.47 (1.54, 18.95) 4.71 imada (2) 2012 4.47 (1.54, 18.95) 4.71 imada (2) 2011 2.62 (1.14, 4.20) 17.48 ima(2-2) 2011 2.54 (1.06, 6.25) 9.44 inuma(1-2) 2011 2.94 (1.06, 6.25) 9.44 inuma(2-2) 2011 2.94 (2.09, 4.14) 63.76 voltati (I-squared = 0.0%, p = 0.432) 3.20 (2.44, 4.21) 100.00 re: Weights are from random effects analysis 00563 1 178	btotal (I-squared = 0.0%, p = 0.599)	0	3.72 (2.36, 5.85)	36.24	Subtotal (I-squared = 22.4%, p = 0.258)	2.77 (1.90, 4.02)	48.31
(2) 2013 1.37 (0.28, 6.78) 2.93 Liu (2) 2013 1.83 (0.61, 5.52) 4.20 (2) 2013 2.57 (1.42, 4.63) 21.28 Yokobori (2) 2013 2.19 (1.10, 4.34) 10.80 (bobori (4) 2013 7.01 (2.80, 19.41) 7.93 Yokobori (2) 2013 4.37 (1.54, 18.95) 4.71 (12) 2011 4.47 (1.54, 18.95) 4.71 Shimada (2) 2012 3.50 (1.42, 10.54) 5.08 (12) 2011 2.62 (1.14, 4.20) 17.48 linuma(1-2) 2011 3.20 (1.44, 6.40) 9.15 (1-squared = 0.0%, p = 0.432) 2.94 (1.06, 6.25) 9.44 linuma(2-2) 2011 3.00 (2.19, 4.11) 5.69 trail (I-squared = 0.0%, p = 0.608) 3.20 (2.44, 4.21) 100.00 Overall (I-squared = 0.0%, p = 0.560) 2.90 (2.32, 3.64) 100.00 NOTE: Weights are from random effects analysis 0.0681 1 11.6	age III				Stage III		
Abbori (2) 2013 - 2.57 (1.42, 4.63) 21.28 Yokobori (2) 2013 kobori (4) 2013 - 7.01 (2.80, 19.41) 7.93 Yokobori (2) 2013 imada (2) 2012 - 4.47 (1.54, 18.95) 4.71 Shimada (2) 2012 ima(1-2) 2011 - 2.62 (1.14, 4.20) 17.48 Iinuma(2-2) 2011 imata(2) 2012 - 2.47 (1.06, 6.25) 9.44 Iinuma(2-2) 2011 intag(2-2) 2011 2.94 (2.09, 4.14) 63.76 Subtotal (I-squared = 0.0%, p = 0.729) 3.00 (2.19, 4.11) 51.69 erall (I-squared = 0.0%, p = 0.608) 3.20 (2.44, 4.21) 100.00 Overall (I-squared = 0.0%, p = 0.560) 2.90 (2.32, 3.64) 100.00 TE: Weights are from random effects analysis - 11.6 - 11.6	(2) 2013	•	1.37 (0.28, 6.78)	2.93	Liu (2) 2013	1.83 (0.61, 5.52)	4.20
kobori (4) 2013 7.01 (2.80, 19.41) 7.93 Yokobori (4) 2013 mada (2) 2012 4.47 (1.54, 18.95) 4.71 Shimada (2) 2012 ima(2-2) 2011 2.62 (1.14, 4.20) 17.48 linuma(1-2) 2011 ima(2-2) 2011 2.47 (1.06, 6.25) 9.44 linuma(1-2) 2011 btotal (I-squared = 0.0%, p = 0.432) 2.94 (2.09, 4.14) 63.76 Subtotal (I-squared = 0.0%, p = 0.560) TE: Weights are from random effects analysis 00563 1 178 00561 1	kobori (2) 2013		2.57 (1.42, 4.63)	21.28	Yokobori (2) 2013	2.19 (1.10, 4.34)	10.80
mada (2) 2012 4.47 (1.54, 18.95) 4.71 Shimada (2) 2012	kobori (4) 2013		7.01 (2.80 19.41)	7.93	Yokobori (4) 2013	4.37 (2.15, 8.94)	10.02
mma(1-2) 2011 2.62 (1.14, 4.20) 17.48 Immun(2-2) 2011 imag(2-2) 2011 2.42 (1.14, 4.20) 17.48 Immun(2-2) 2011 btotal (I-squared = 0.0%, p = 0.432) 2.94 (2.09, 4.14) 63.76 Subtotal (I-squared = 0.0%, p = 0.729) erall (I-squared = 0.0%, p = 0.608) 3.20 (2.44, 4.21) 100.00 Overall (I-squared = 0.0%, p = 0.560) 2.90 (2.32, 3.64) TE: Weights are from random effects analysis 17.8 0.061 1 11.6	imada (2) 2012		4.47 (1.54 18.95)	4.71	Shimada (2) 2012	3 50 (1 42 10 54)	5.08
minute(1-2) 2011 2.47 (1.16, 6.25) 10.06 (2.5) 9.44 inuma(2-2) 2011 2.47 (1.16, 6.25) 9.44 bitotal (I-squared = 0.0%, p = 0.432) 2.94 (2.09, 4.14) 63.76 erall (I-squared = 0.0%, p = 0.608) 3.20 (2.44, 4.21) 100.00 Dverall (I-squared = 0.0%, p = 0.560) 2.90 (2.32, 3.64) 100.00 TE: Weights are from random effects analysis 00563 1 178	ma(1-2) 2011		2 62 (1 14 4 20)	17 48	linuma(1-2) 2011	3 26 (1 74 6 25)	12 45
bitotal (I-squared = 0.0%, p = 0.432) 2.94 (2.09, 4.14) 63.76 Subtotal (I-squared = 0.0%, p = 0.729) 3.00 (2.19, 4.11) 51.69 verail (I-squared = 0.0%, p = 0.608) 3.20 (2.44, 4.21) 100.00 Overail (I-squared = 0.0%, p = 0.560) 2.90 (2.32, 3.64) 100.00 TE: Weights are from random effects analysis NOTE: Weights are from random effects analysis 11.6	uma(2-2) 2011		2.47 (1.06 6.25)	9.44	linuma(2-2) 2011	2 97 (1.44, 6.40)	9.15
erall (I-squared = 0.0%, p = 0.608) 3.20 (2.44, 4.21) 100.00 Overall (I-squared = 0.0%, p = 0.560) 2.90 (2.32, 3.64) 100.00 TE: Weights are from random effects analysis NOTE: Weights are from random effects analysis 00563 1 11.6	btotal (I-squared = 0.0%, p = 0.432)	0	2.94 (2.09, 4.14)	63.76	Subtotal (I-squared = 0.0%, p = 0.729)	3.00 (2.19, 4.11)	51.69
TE: Weights are from random effects analysis 00553 1 178 00563 1 178 00661 1 118	erall (I-squared = 0.0%, p = 0.608)	0	3.20 (2.44, 4.21)	100.00	Overall (I-squared = 0.0%, p = 0.560)	2.90 (2.32, 3.64)	100.00
	TE: Weights are from random effects analysis				NOTE: Weights are from random effects analysis		
.0001							

prognostic information with approximately 93% 5-year stage-specific survival rate for stage I, 84% for stage II, and 83% for stage III [40] and is influenced by clinico-pathological parameters such as vascular invasion, poor

differentiation, tumor size and serum tumor markers (i.e., carcinoembryonic antigen, CEA). Recently, many molecular biomarkers and high-risk gene signatures have been demonstrated to provide further information



to support clinical decisions, however, none were conclusively accurate to evaluate the prognosis of all patients.

Since CTCs were first identified in PB of CRC patients, the clinical value of CTCs had become a debated topic throughout the medical community. From the clinical perspective, CTC analyses has an advantage in terms of a cost and ease of operation to serve as a monitoring tool pre and post treatments. Numerous studies had demonstrated that CTCs detection could provide

important prognostic information for patients with CRC. A previous meta-analysis by Groot et al. had demonstrated the prognosis significance of detection of CTCs in patients with mCRC [41]. Peach et al. reviewed the prognostic value of postoperative detection of CTCs in non-mCRC patients and concluded that the presence of CTCs in PB was an independent predictor of recurrence [42]. However, the two meta-analyses were limited by the presence of meth-odological heterogeneity; the included studies used several different methods to detect CTCs and were not stratified

Table 3 Results of subgroup analyses on OS

Variables	HR[95%CI]	Number	²	P ^d
Year > median ^a				
Yes	3.65[2.49-5.36]	6	0.00%	0.578
No	2.44[1.19-4.99]	7	72.90%	0.001
Country				
East Asia	3.39[2.27-5.05]	10	46.50%	0.051
Non-East Asia	2.10[0.52-8.54]	3	74.50%	0.02
Marker				
Single	2.72[1.48-5.00]	9	66.80%	0.002
Multiple	3.77[2.62-5.43]	4	0.00%	0.799
Sampling time poi	int			
Pre-op	3.65[2.49-5.36]	6	0.00%	0.578
Intra/post-op	2.44[1.19-4.99]	7	72.90%	0.001
Patient no. > med	ian ^b			
Yes	3.45[2.57-4.65]	6	0.00%	0.801
No	2.59[1.08-6.22]	7	74.20%	0.001
Detection rate > n	nean ^c			
Yes	1.57[0.42-5.79]	4	74.10%	0.009
No	3.71[2.84-4.85]	9	0.00%	0.796
Quality of study				
Low	4.06[1.64-10.05]	2	0.00%	0.384
High	2.95[1.87-4.65]	11	61.50%	0.004
Overall	3.07[2.05-4.62]	13	55.70%	0.008

NOTE: ^aThe median year for OS was 2012

^bThe median patient no. for OS was 103

^cThe mean detection rate for OS was 38.12% ^dTwo-tailed P value of tests for heterogeneity

by detection method. With regard to the detection methods of CTCs, the prognostic utility of the CellSearch system in CRC patients had been demonstrated by a metaanalysis [43]. However, the clinical application of the RT-PCR approach in the non-mCRC patients has still not been illustrated by a large-scale data analysis.

This study is the first comprehensive meta-analysis to validate the clinical significance of CTC detection by RT-

Table 4 Results of meta-regression on OS

	neta regre	551011 011 0	0	
Variables	Coef. ^a	Std. Err. ^b	P value	Adj R-squared ^c
Year	0.5072	0.4559	0.2900	0.67%
Country	0.5352	0.5770	0.3740	1.08%
Marker	0.4133	0.5021	0.4280	-11.42%
Time point	-0.5072	0.4559	0.2900	0.67%
Patient no.	0.3751	0.4688	0.4410	-10.13%
Detection rate(mean)	-1.1526	0.4288	0.0210	93.80%
Quality of study	-0.3412	0.7123	0.6410	-12.93%

NOTE: ^aCoef.: coefficient

^bStd. Err.: standard Error

^cAdj R-squared: Proportion of between-study variance explained

PCR method only in non-mCRC. The results demonstrated that CTC-positive patients had poorer OS and DFS than CTCs-negative patients at different sampling time (pre-OP and intra/post-OP), TNM stage (II/III) and adjuvant therapy status (without/post-OP chemotherapy), indicating that the clinical prognosis of patients with non-mCRC is significantly associated with the CTCs detected by RT-PCR in PB. Our pooled analyses also assessed the association between CTCs and clinicopathological parameters of non-mCRC patients and showed that CTC-positive was correlated with regional lymph nodes metastasis, deep depth of tumor infiltration, vascular invasion, poor differentiation of tumor and later TNM stage. Moreover, all these parameters have been shown to be an indicators of poor prognosis in CRC patients. Combined with the results of our collective evaluation, CTC-positive in PB has been demonstrated to be considered a prognostic and predictive marker for patients with non-mCRC. Numerous studies have demonstrated that there was not relationship between tumor size and the positivity of CTCs detection [28, 35]; the results of our study were consistent with these previous studies.

Although we limited the studies included in our metaanalysis to those that used RT-PCR to reduce the heterogeneity caused by the difference in detection methods, no significant heterogeneity was found in the pooled analysis of DFS ($I^2 = 34.0\%$, P = 0.085). Nevertheless, there was still a certain extent of heterogeneity in our meta-analysis. Especially for OS, heterogeneity was mainly caused by data from the study by Shimada et al. [19]. Heterogeneity may also come from differences in the year, country and quality of publication, along with differences in sampling time, detection marker, or detection rate. Differences in the experimental designs in the cohort studies also generated non-negligible heterogeneity. To explore the potential sources of heterogeneity, subgroup analyses were performed based on year, country and quality of publication, sampling time, marker, number of patients, or detection rate, but the results were inconclusive (Table 3). Further, the results of the meta-regression clarified the heterogeneity and showed the detection rate was mainly responsible for the heterogeneity on OS. The detection rate of CTCs was greatly different based on different stage of early CRC. Stage I was too low, however, and the CTC-positive rate was significantly increased in stage III CRC patients, which had already been confirmed in studies using the Cell-Search system [14, 15].

Theoretically, the association between prognosis and post-OP CTCs status was more convincing because post-OP CTCs status contains pre-OP CTCs and released CTCs during the operation [44]. However, the rapid apoptotic death of pre-OP CTCs may release mass tumor genes or antigens due to the change of the



survival microenvironment in the process of operation, which might lead to a certain degree of detection bias. Therefore, the samples of post-OP samples could more accurately reflect the CTC status by including CTC release, apoptosis, and necrosis and could provide more information about the prognosis of patients. Ikeguchi M et al. [45] found that in blood samples collected within 48 h after the operation, patients with CTC-positive had better prognosis than CTCsnegative patients. In our meta-analysis, the estimated result for OS remained stable and was not significantly affected by sampling time, which indicated CTCs detection not only at pre-OP but also post-OP could provide a prognostic factor. Thus, uncertainties still remain that sampling time could provide more accurate prognostic information, and further studies are needed to evaluate this relationship.

There were several limitations in our meta-analysis. First, our data for the meta-analysis came from previously published studies, and several included studies did not report HR. Therefore, we had to calculate them from the reported data with limited access to the raw data, which might affect the accuracy of the results. Second, there was considerable heterogeneity in our study. Although we eliminated the heterogeneity from detection methodology, RT-PCR cannot achieve CTCs enumeration and lacks biologic specificity. However, it does have the advantage of high sensitivity for CTCs detection [46]. We addressed the between-study heterogeneity by using a random effects model to obtain more conservative estimates. Third, language selection brings bias. We restricted the eligible studies to those written in English and excluded the relevant studies of other languages according to language criteria, which may cause language bias leading to an overestimation of effect sizes [47]. Despite these limitations, our meta-analysis is the first study to assess the prognostic significance of CTCs detected by RT-PCR in non-mCRC patients. Our results provides an example for other studies that standardized testing method, optimized sampling time, complete analysis and report of results should be used to derive more accurate prognostic significance of CTCs in non-mCRC and CRC patients.

Conclusions

Based on available evidence, our meta-analysis suggested that the detection of CTCs in PB by RT-PCR is a prognostic factor for patients with non-mCRC, and CTC-positive was associated with poor prognosis and poor clinicopathological prognostic factors. However, the prognostic value of CTCs supports the use of CTCs as an indicator of metastatic disease prior to the current classification of mCRC meaning it is detectable by CT/MRI. Further highquality, well-designed, large-scale multicenter studies are required to evaluate the clinical significance and utility of CTCs detected by RT-PCR in non-mCRC patients.

Abbreviations

CIs: Confidence intervals; CRC: Colorectal cancer; CT: Chemotherapy; CTCs: Circulating tumor cells; DFS: Disease-free survival; HR: Hazard ratio; mCRC: Metastatic CRC; non-mCRC: Non-metastatic CRC; OP: Operative; OS: Overall survival; PB: Peripheral blood; RLNs: Regional lymph nodes; RR: Relative risk; RT-PCR: Reverse-transcriptase polymerase chain reaction; TNM: Tumor-node-metastasis

Acknowledgements

Not applicable

Funding

This work was supported by National Natural Science Foundation of China (No. 81572874). The funding body was not involved in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article.

Authors' contributions

CY and KZ contributed equally to this work. CY, KZ, and BX were responsible for conception and design of the study. CY and KZ did the studies selection, data extraction, statistical analyses and writing of the manuscript. LZ participated in studies selection and data extraction, and provided statistical expertise. CY, KZ and LZ contributed to the literature search, studies

selection, and figs. CY, KZ and ZW provided clinical expertise and interpretation of data. The report was drafted, revised, and approved by all investigators. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Gastrointestinal Surgery & Department of Gastric and Colorectal Surgical Oncology, Zhongnan Hospital of Wuhan University; Hubei Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study Center, No.169 Donghu Road, Wuchang District, Wuhan 430071, China. ²Department of Oncology, Central Hospital of Wuhan, No.16 Gusaoshu Road, Jianghan District, Wuhan 430014, China.

Received: 26 November 2016 Accepted: 25 October 2017 Published online: 07 November 2017

References

- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
- Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.
- Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544–73.
- Hayashi M, Inoue Y, Komeda K, Shimizu T, Asakuma M, Hirokawa F, Miyamoto Y, Okuda J, Takeshita A, Shibayama Y, et al. Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis. BMC Surg. 2010;10:27.
- Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003;3(6):453–8.
- 6. Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869;14(3):146–9.
- Engell HC. Cancer cells in the circulating blood; a clinical study on the occurrence of cancer cells in the peripheral blood and in venous blood draining the tumour area at operation. Acta chirurgica Scandinavica Supplementum. 1955;201:1–70.
- 8. Pantel K, Alix-Panabieres C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16(9):398–406.
- Tibbe AG, Miller MC, Terstappen LW. Statistical considerations for enumeration of circulating tumor cells. Cytometry Part A. 2007;71(3):154–62.
- Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 2007;253(2):180–204.
- Seeberg LT, Waage A, Brunborg C, Hugenschmidt H, Renolen A, Stav I, Bjornbeth BA, Brudvik KW, Borgen EF, Naume B, et al. Circulating tumor cells in patients with colorectal liver metastasis predict impaired survival. Ann Surg. 2015;261(1):164–71.
- Aggarwal C, Meropol NJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol. 2013;24(2):420–8.
- Sotelo MJ, Sastre J, Maestro ML, Veganzones S, Vieitez JM, Alonso V, Gravalos C, Escudero P, Vera R, Aranda E, et al. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer. Ann Oncol. 2015;26(3):535–41.
- Kuboki Y, Matsusaka S, Minowa S, Shibata H, Suenaga M, Shinozaki E, Mizunuma N, Ueno M, Yamaguchi T, Hatake K. Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as

biomarkers for cetuximab efficacy in advanced colorectal cancer. Anticancer Res. 2013;33(9):3905–10.

- Bork U, Rahbari NN, Scholch S, Reissfelder C, Kahlert C, Buchler MW, Weitz J, Koch M. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br J Cancer. 2015;112(8):1306–13.
- Zhe X, Cher ML, Bonfil RD. Circulating tumor cells: finding the needle in the haystack. Am J Cancer Res. 2011;1(6):740–51.
- Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Janicke F, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007;13(3):920–8.
- Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10(20):6897–904.
- Shimada R, linuma H, Akahane T, Horiuchi A, Watanabe T. Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients. Oncol Rep. 2012;27(4):947–53.
- Kust D, Samija I, Kirac I, Radic J, Kovacevic D, Kusic Z. Cytokeratin 20 positive cells in blood of colorectal cancer patients as an unfavorable prognostic marker. Acta Clin Belg. 2016;71(4):235–43.
- Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
- 22. Smith T, Smith B, Ryan MA. Survival analysis using Cox proportional hazards modeling for single and multiple event time data. In: Proceedings of the twenty-eighth annual SAS users group international conference, SAS Institute, inc, Cary, paper; 2003. p. 228–54.
- Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.
- 24. Schmidt FL, Oh IS, Hayes TL. Fixed- versus random-effects models in metaanalysis: model properties and an empirical comparison of differences in results. The British journal of mathematical and statistical psychology. 2009; 62(Pt 1):97–128.
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539.
- 26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.
- 27. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.
- Liu Y, Qian J, Feng JG, Ju HX, Zhu YP, Feng HY, Li DC. Detection of circulating tumor cells in peripheral blood of colorectal cancer patients without distant organ metastases. Cell Oncol. 2013;36(1):43–53.
- Yokobori T, Iinuma H, Shimamura T, Imoto S, Sugimachi K, Ishii H, Iwatsuki M, Ota D, Ohkuma M, Iwaya T, et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 2013;73(7):2059–69.
- linuma H, Watanabe T, Mimori K, Adachi M, Hayashi N, Tamura J, Matsuda K, Fukushima R, Okinaga K, Sasako M, et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol. 2011;29(12):1547–55.
- Uen YH, CY L, Tsai HL, FJ Y, Huang MY, Cheng TL, Lin SR, Wang JY. Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I-III colorectal cancer after curative resection. Ann Surg Oncol. 2008;15(8):2120–8.
- Barreto G, Neve R, Shrikhande SV, Shukla PJ. Role of circulating tumour cells in predicting recurrence after excision of primary colorectal carcinoma (Br J Surg 2007; 94: 96-105). Br J Surg. 2007;94(5):644. author reply 644-645
- Koch M, Kienle P, Kastrati D, Antolovic D, Schmidt J, Herfarth C, von Knebel Doeberitz M, Weitz J. Prognostic impact of hematogenous tumor cell dissemination in patients with stage II colorectal cancer. Int J Cancer. 2006; 118(12):3072–7.
- Lloyd JM, McIver CM, Stephenson SA, Hewett PJ, Rieger N, Hardingham JE. Identification of early-stage colorectal cancer patients at risk of relapse postresection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells. Clin Cancer Res. 2006;12(2):417–23.
- Sadahiro S, Suzuki T, Ishikawa K, Saguchi T, Maeda Y, Yasuda S, Makuuchi H, Yurimoto S, Murayama C. Detection of carcinoembryonic antigen messenger RNA-expressing cells in portal and peripheral blood during

surgery does not influence relapse in colorectal cancer. Ann Surg Oncol. 2005;12(12):988–94.

- Bessa X, Pinol V, Castellvi-Bel S, Piazuelo E, Lacy AM, Elizalde JI, Pique JM, Castells A. Prognostic value of postoperative detection of blood circulating tumor cells in patients with colorectal cancer operated on for cure. Ann Surg. 2003;237(3):368–75.
- 37. Ito S, Nakanishi H, Hirai T, Kato T, Kodera Y, Feng Z, Kasai Y, Ito K, Akiyama S, Nakao A, et al. Quantitative detection of CEA expressing free tumor cells in the peripheral blood of colorectal cancer patients during surgery with real-time RT-PCR on a LightCycler. Cancer Lett. 2002;183(2):195–203.
- Treanor D, Quirke P. Pathology of colorectal cancer. Clin Oncol. 2007; 19(10):769–76.
- Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O'Callaghan C, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872–7.
- Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart A. Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol. 2010;28(2):256–63.
- Groot Koerkamp B, Rahbari NN, Buchler MW, Koch M, Weitz J. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol. 2013;20(7):2156–65.
- Peach G, Kim C, Zacharakis E, Purkayastha S, Ziprin P. Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review. Br J Cancer. 2010;102(9):1327–34.
- Huang X, Gao P, Song Y, Sun J, Chen X, Zhao J, Xu H, Wang Z. Metaanalysis of the prognostic value of circulating tumor cells detected with the CellSearch system in colorectal cancer. BMC Cancer. 2015;15:202.
- Weitz J, Kienle P, Lacroix J, Willeke F, Benner A, Lehnert T, Herfarth C, von Knebel Doeberitz M. Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res. 1998;4(2):343–8.
- 45. Ikeguchi M, Kaibara N. Detection of circulating cancer cells after a gastrectomy for gastric cancer. Surg Today. 2005;35(6):436–41.
- 46. Wicha MS, Hayes DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol. 2011;29(12):1508–11.
- Pham B, Klassen TP, Lawson ML, Moher D. Language of publication restrictions in systematic reviews gave different results depending on whether the intervention was conventional or complementary. J Clin Epidemiol. 2005;58(8):769–76.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit

